Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 15Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Chronic-Phase 10Recurrence 8Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Neoplasm Metastasis 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Burkitt Lymphoma 5Pancreatic Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasms 3Lymphoma 3Gliosarcoma 3Sarcoma 2Salivary Gland Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Polycythemia Vera 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

imetelstat 1entinostat 1GRN163L peptide 1Everolimus 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Stem Neoplasms × Dasatinib × Clear all
NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

University of Michigan Rogel Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
CNS

Glioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡